Dr. med. Dennis Kannenkeril
Oberarzt, Internist, Facharzt für Innere Medizin und Nephrologie, Hypertensiologe (DHL), ESH Clinical Hypertension Specialist
Lebenslauf, Veröffentlichungen und Auszeichnungen
Publikationen
- (2023) The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. Clin Res Cardiol. 2023;112(1): 134-144
- (2023) Is vascular remodelling in patients with chronic heart failure exaggerated? ESC Heart Fail. 2023;10(1): 245-254
- (2023) Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure. ESC Heart Fail. 2023;10(3): 1635-1642
- (2022) The influence of aircraft noise exposure on the systemic and renal haemodynamics. Eur J Prev Cardiol. 2022;29(1): 116-124
- (2022) Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range. Diabetes Care. 2022;45(6): 1472-1475
- (2022) Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study. Diabetol Metab Syndr. 2022;14(1):
- (2022) Evolocumab Alters Vascular Function in Patients With Cardiovascular Disease Circulation. 2022;146 Suppl 1():
- (2022) ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE J Hypertens. 2022;40 Suppl 1(SUPPL 1): E283-E284
- (2022) IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES J Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
- (2022) SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
- (2022) SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
- (2022) IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES J Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
- (2022) DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL 1): E129-E129
- (2022) DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E129-E129
- (2022) Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022;21(1):
- (2022) Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. J Hum Hypertens. 2022;36(9): 811-818
- (2021) Microvascular changes at different stages of chronic kidney disease. J Clin Hypertens (Greenwich). 2021;23(2): 309-316
- (2021) Supine blood pressure-A clinically relevant determinant of vascular target organ damage in hypertensive patients. J Clin Hypertens (Greenwich). 2021;23(1): 44-52
- (2021) Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021;8(2): 1562-1570
- (2021) Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021;20(1):
- (2021) Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6): 5327-5337
- (2021) Association of Noise Annoyance with Measured Renal Hemodynamic Changes. Kidney Blood Press Res. 2021;46(3): 323-330
- (2021) Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021;35(12):
- (2021) Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure. J Hypertens. 2021;39(9): 1826-1834
- (2021) Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors. J Hypertens. 2021;39(7): 1352-1360
- (2021) Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20(1):
- (2021) Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin Eur Heart J. 2021;42 Suppl 1(): 795-795
- (2021) Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failure Diabetologia. 2021;64 Suppl 1(SUPPL 1): 107-107
- (2021) Angiotensin profiles in patients with type 2 diabetes and combination therapy of empagliflozin and linagliptin versus metformin and insulin glargine Diabetologia. 2021;64 Suppl 1(SUPPL 1): 256-256
- (2021) Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. Am J Nephrol. 2021;52(1): 69-75
- (2021) Dependency of flow-mediated vasodilatation from basal nitric oxide activity. Clin Physiol Funct Imaging. 2021;41(4): 310-316
- (2021) Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021;77(6): 1825-1844
- (2021) RELATION BETWEEN NOISE ANNOYANCE, STRESS HORMONES AND THE RENAL HEMODYNAMIC J Hypertens. 2021;39 Suppl 1(): E178-E178
- (2021) ANNOYANCE DUE TO NOISE TRIGGERS VASCULAR CHANGES IN THE RENAL HEMODYNAMIC J Hypertens. 2021;39 Suppl 1(): E169-E169
- (2021) LOW DOSE-EPLERENONE TREATMENT DECREASES AORTIC STIFFNESS IN PATIENTS WITH METABOLIC SYNDROME J Hypertens. 2021;39 Suppl 1(): E338-E338
- (2021) DETECTION OF CHANGES IN RENAL BLOOD FLOW USING ARTERIAL SPIN LABELING MRI J Hypertens. 2021;39 Suppl 1(): E307-E307
- (2021) CAN WE IDENTIFY GLOMERULAR HYPERFILTRATION IN PATIENTS WITH TYPE 2 DIABETES BY CLINICAL PARAMETERS? J Hypertens. 2021;39 Suppl 1(): E211-E211
- (2021) THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE J Am Coll Cardiol. 2021;77 Suppl 1(18): 585-585
- (2021) EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE J Am Coll Cardiol. 2021;77 Suppl 1(18): 1806-1806
- (2020) Validation of semi-automated flow-mediated dilation measurement in healthy volunteers. Blood Press Monit. 2020;25(4): 216-223
- (2020) Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2020;6(6): 364-371
- (2020) Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. Sci Rep. 2020;10(1):
- (2020) Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. Am J Hypertens. 2020;33(2): 182-189
- (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234): 1444-1451
- (2019) How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):
- (2019) Tissue sodium content in patients with type 2 diabetes mellitus. J Diabetes Complications. 2019;33(7): 485-489
- (2019) Evidence of neurodegeneration in individuals with only mildly elevated blood pressure. J Hypertens. 2019;37(12): 2389-2397
- (2018) Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):
- (2018) THE INFLUENCE OF ANNOYANCE DUE TO NOISE ON RENAL HEMODYNAMIC J Hypertens. 2018;36(): E39-E39
- (2018) DIFFERENT RESPONSE PATTERN TO AIRCRAFT NOISE EXPOSURE IN RENAL VERSUS SYSTEMIC HEMODYNAMIC J Hypertens. 2018;36(): E138-E138
- (2018) COPEPTIN AS A RESEARCH MARKER IN CARDIOVASCULAR DISEASE J Hypertens. 2018;36(): E35-E35
- (2018) How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Eur Heart J. 2018;39(): 869-869
- (2018) EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETES J Hypertens. 2018;36(): E9-E9
- (2018) Retinal vascular resistance in arterial hypertension. Blood Press. 2018;27(2): 82-87
- (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17(1): 5
- (2017) Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. Circulation. 2017;136(12): 1167-1169
- (2016) Experience with belatacept rescue therapy in kidney transplant recipients. Transpl Int. 2016;29(11): 1184-1195
Sprechstunden
Bluthochdruck (schwer einstellbar)
Spezialsprechstunde
Dr. med. Dennis Kannenkeril
Prof. Dr. med. Karl F. Hilgers
Zeiten
Montags ab 11 Uhr nur nach Vereinbarung
Internistisches Zentrum (INZ)
Ulmenweg 18
91054 Erlangen
Raum
D 0 723-1
Terminvergabe nur nach Absprache
siehe "Hinweis"
Hinweis
In dieser Sprechstunde werden Patienten mit schwer einstellbarer arterieller Hypertonie und sekundären Formen der Hypertonie behandelt.
Für diese Sprechstunde ist eine vorherige Terminvereinbarung notwendig.
Wir bitten Sie, Ihren betreuenden Hausarzt oder Internisten, uns vorab folgende Unterlagen (soweit indiziert bzw. erhoben) per Fax (an 09131 85-33431) oder per Post zu schicken:
- Überweisungsschein vom Facharzt für Nephrologie
- ggf. Überweisungsschein für das Medizinische Labor Bremen (Urinscreening auf antihypertensive Substanzen)
- Medikamentenplan
- Blutwerte/Urinuntersuchung
- Blutbild
- Kalium, Natrium, Chlorid, Kreatinin, Harnstoff, Harnsäure, nüchtern bestimmte Blutfettwerte, nüchtern bestimmte Glucose
- TSH basal
- Aldosteron, Renin
- Urin-Albumin/Kreatinin-Verhältnis
- Ruhe-EKG
- 24h-Langzeit-Blutdruckmessung
- bisher vorliegende internistische Arztbriefe von ambulanten Vorstellungen/stationären Aufenthalten
Bitte denken Sie daran, Ihre Kontaktdaten bzw. die des Patienten anzugeben (Name, Adresse, Telefonnummer).
Diese Unterlagen werden dem zuständigen Oberarzt vorgelegt. Erst danach werden Sie zur Terminvereinbarung von uns angerufen oder angeschrieben.
Mitzubringen
- Versicherungsnachweis (Krankenkassenkarte)